Showing 8151-8160 of 9548 results for "".
- Merz Taps Bob Rhatigan as New President, CEOhttps://practicaldermatology.com/news/merz-taps-bob-rhatigan-as-new-president-ceo/2458229/Allergan vet Bob Rhatigan is the new President and Chief Executive Officer (CEO) of Merz North America, and Patrick Urban will serve as Chief Commercial Officer, effective immediately. In his new role, Mr. Rhatigan will assume responsibility for Merz&rsq
- Heliocare Spotlights Improved Formulation: Vegan, Gluten-free, and Dye-freehttps://practicaldermatology.com/news/heliocare-spotlights-improved-formulation-vegan-gluten-free-and-dye-free/2458243/Heliocare Daily Use Antioxidant Formula, a clinically proven, natural dietary supplement with antioxidant effects on the skin, has been updated to be vegan, gluten-free, and free of artificial dyes. The once-daily capsules from Ferndale Healthcare, have been recommended by dermatologists fo
- RepliCel's Baldness Cure Performs Well In First In-Human Trialhttps://practicaldermatology.com/news/replicels-baldness-cure-performs-well-in-first-in-human-trial/2458246/The first in-human study of RepliCel Life Sciences Inc’s investigational baldness cure, RCH-01, confirms the therapy’s safety and demonstrates strong efficacy signals, the company reports. The autologous cell therapy involves culturing a person’s own dermal sheath cup ce
- Serlopitant May Stop the Itch of Prurigo Nodularishttps://practicaldermatology.com/news/serlopitant-may-stop-the-itch-of-prurigo-nodularis/2458252/Menlo Therapeutics Inc.’s Serlopitant performed well in phase 2 trial (TCP-102) evaluating it as a treatment of pruritus associated with prurigo nodularis, successfully meeting its primary efficacy endpoint and key sec
- New Biomarker May Help Guide Metastatic Melanoma Treatment Decisionshttps://practicaldermatology.com/news/new-biomarker-may-guide-metastatic-melanoma-treatment-decisions/2458253/Measuring levels of Bim—a protein made by cancer-fighting T cells—via a simple blood draw can help doctors predict which metastatic melanoma patients would benefit from anti-PD-1 checkpoint blockade. Such personalized medicine can help eliminate some of the trial and error ass
- Galderma Moves to Differentiate Their Two New HA Fillers From The Frayhttps://practicaldermatology.com/news/galderma-moves-to-differentiate-their-two-new-ha-fillers-from-the-fray/2458262/With a growing number of hyaluronic acid (HA) fillers available and even more in the pike, Galderma is highlighting how their two newest fillers --Restylane Refyne and Restylane Defyne --stand out from the crowd. In a word: flexibility. Th
- Galderma and Colorescience Launch Collaborationhttps://practicaldermatology.com/news/galderma-and-colorescience-launch-collaboration/2458265/Galderma will collaborate with Colorescience to expand skincare solutions to individuals who seek innovative daily skincare products that can be used in conjunction with traditional facial injectable aesthetic treatments, the companies have announced. Galderma and Color
- Skin Diseases Remain Major Cause of Disabilityhttps://practicaldermatology.com/news/skin-diseases-remain-major-cause-of-disability/2458267/Skin diseases are the fourth leading cause of disability worldwide, according to the Global Burden of Disease 2013 Study which appears online in JAMA Dermatology. For the study, researchers estimate
- Olay Rolls Out The Olay Skin Advisor 2.0https://practicaldermatology.com/news/olay-rolls-out-the-olay-skin-advisor-20/2458270/Olay’s new
- Ray Canole is New Chief Commercial Officer at Revision Skincarehttps://practicaldermatology.com/news/ray-canole-is-new-chief-commercial-officer-at-revision-skincare/2458287/Revision Skincare has announced the appointment of Ray Canole to the position of Chief Commercial Officer. He has over 15 years of business development and commercial related experience in dermatology-focused organizations and joins Revision from Renaissance Pharma, where he helped